| Over a week ago | ||||
EF Hutton assumed… EF Hutton assumed coverage of Werewolf Therapeutics with a Buy rating and $8.30 price target. Werewolf's clinical-stage candidates are WTX-124 and WTX-330, and initial human data from WTX-124 are expected in 4Q23, which may provide proof of principle for the platform as well as proof of activity for WTX-124, the analyst tells investors in a research note. | ||||
BofA analyst Jason… BofA analyst Jason Zemansky raised the firm's price target on Werewolf Therapeutics to $10 from $9 and keeps a Buy rating on the shares following what the firm describes as "another solid quarter." The firm continues to see a "compelling risk/ reward for shares" given Werewolf confirmed enrollment of a phase 1/1b trial of IL-2 candidate '124 remains ongoing, phase 1 dosing is also underway for IL-12 candidate '330, a "cytokine with arguably greater potential," and pre-clinical IL-21 asset '712 is moving forward as well. | ||||
Reports Q1 revenue… Reports Q1 revenue $4.464M vs $0 last year. "In the first quarter, Werewolf has focused on execution by progressing our INDUKINE pipeline and enrolling ongoing first-in-human clinical trials for our lead programs, WTX-124 and WTX-330. In addition, preclinical data presented at AACR and published in Cancer Immunology Research continues to demonstrate the robustness of our PREDATOR platform showing that Werewolf's conditional activation technology results in potent anti-tumor activity alongside an improved therapeutic index," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "Looking ahead, in the fourth quarter we plan to share initial safety, tolerability, and preliminary efficacy data from our Phase 1/1b clinical trial of WTX-124 in solid tumor types." | ||||
| Over a month ago | ||||
Werewolf Therapeutics… Werewolf Therapeutics announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 INDUKINE molecule. The article, entitled "mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity," includes preclinical data that demonstrates that mWTX-330 delivers IL-12 selectively to the tumor microenvironment, where it stimulates a potent anti-tumor immune response. Other key findings and data outlined in the article include: mWTX-330 treatment generates a robust, cleavage-dependent anti-tumor immune response in multiple syngeneic tumor models and is well tolerated. mWTX-330 delivery expands the therapeutic window of the IL-12 cytokine. mWTX-330 treatment activates various tumor-infiltrating lymphocyte populations in the MC38 mouse model and results in the transcriptional reprogramming of the tumor microenvironment and the subsequent activation of various tumor-infiltrating effector-cell populations. mWTX-330 treatment expands unique T-cell receptor clones and increases TCR clonality in the tumor microenvironment. mWTX-330 treatment substantially increases mitochondrial activity in tumor infiltrating CD8+ T cells and NK Cells while reducing signs of exhaustion on CD8+ T cells. The fully human WTX-330 INDUKINE molecule is preferentially activated by primary human tumors. Werewolf is currently recruiting patients for a first-in-human, multi-center, open-label Phase 1 clinical trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved. | ||||
H.C. Wainwright analyst… H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Werewolf Therapeutics to $15 from $20 and keeps a Buy rating on the shares. Werewolf continues to make progress with its most advanced Indukine candidate WTX-124 with initial interim safety, tolerability and preliminary efficacy data from the monotherapy cohorts of WTX-124x2101 in Q4 of 2023, the analyst tells investors in a research note. The firm says "patience is required" in Werewolf shares. | ||||
Reports Q4 revenue… Reports Q4 revenue $7.283M, consensus $2.07M. "Werewolf enters 2023 with considerable momentum following exceptional execution across our Company in 2022. In particular, we initiated clinical trials for our two lead INDUKINE programs, WTX-124 and WTX-330, and also advanced our newest IL-21 INDUKINE pipeline candidate WTX-712," said Daniel Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "This year we anticipate multiple catalysts as we progress our two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Also of note, we have extended our cash runway beyond previous guidance and through at least the fourth quarter of 2024, which provides us the opportunity to reach multiple potential value creating milestones." | ||||
| Over a quarter ago | ||||
Werewolf Therapeutics… Werewolf Therapeutics announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330, the Company's lead INDUKINETM molecule targeting Interleukin-12, IL-12. "Dosing the first patient in our Phase 1 trial of WTX-330 marks the second INDUKINE molecule arising from our PREDATORTM protein engineering platform to enter the clinic. Our continued transition into a clinical stage company comes at an exciting time for Werewolf following the initiation of a Phase 1/1b clinical study of WTX-124 last year," said Daniel Hicklin, Ph.D., Werewolf's Founder and Chief Executive Officer. "WTX-330 serves as another example of our team's capacity to expand our clinical pipeline and validates our novel approach of developing conditionally activated cytokines as cancer therapies to improve outcomes for patients with hard-to-treat tumors." | ||||
Shares of Werewolf… Shares of Werewolf Therapeutics are up 12% afterhours at $2.50 per share. In a 13D/A filing, RA Capital has disclosed that it is raising its stake in the stock to 18.0% from 14.6%, also stating: "In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the Issuer, including but not limited to its operations, strategic direction, governance or capitalization, and potential business combinations or dispositions involving the Issuer or certain of its businesses. Dr. Derek DiRocco, a Partner of RA Capital, currently serves as a director of the Issuer and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director." | ||||
EF Hutton analyst Michael… EF Hutton analyst Michael King initiated coverage of Werewolf Therapeutics with a Buy rating and $8.30 price target. Werewolf is an "emerging leader" in the area of engineered cytokines for immuno-therapy of cancer and autoimmune conditions, said King, who adds that the company's PREDATOR platform is designed to overcome the shortcomings of the compounds that came before its clinical stage candidates WTX-124 and WTX-330. | ||||
Werewolf Therapeutics… Werewolf Therapeutics announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer being held November 8-12, 2022, in Boston, and virtually. Study data demonstrate that systemic administration of mWTX-330, a mouse surrogate INDUKINE molecule, generates potent anti-tumor activity in a cleavage-dependent manner and protective memory against re-challenge in multiple murine syngeneic tumor models. Additionally, the data showed substantial infiltration and robust IL-12 signaling in intratumoral CD8+ T cells. Data from the SITC poster presentation demonstrate that mWTX-330: generates robust anti-tumor immunity following activation in the tumor microenvironment; activates multiple immune cell populations, including CD8+ T cells, CD4+ T cells, and NK cells; protects against later rechallenge with the same tumor cell line in mice that rejected primary tumors; is better tolerated than chimeric IL-12, significantly expanding the therapeutic window of this cytokine due to the INDUKINE molecule design. | ||||
